Jane Street Group, LLC Kodiak Sciences Inc. Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	BUY	$7.09 - $89.45 $827,403 - $10.4 Million	116,700 Added 1100.94%	127,300 $983,000
Q4 2021 Feb 15, 2022	SELL	$80.85 - $128.49 $1.54 Million - $2.44 Million	-19,000 Reduced 64.19%	10,600 $899,000
Q3 2021 Nov 16, 2021	BUY	$81.97 - $106.94 $1.16 Million - $1.52 Million	14,200 Added 92.21%	29,600 $2.84 Million
Q2 2021 Aug 16, 2021	SELL	$77.2 - $126.54 $2.64 Million - $4.33 Million	-34,200 Reduced 68.95%	15,400 $1.43 Million
Q1 2021 May 18, 2021	BUY	$110.45 - $164.47 $2.3 Million - $3.42 Million	20,800 Added 72.22%	49,600 $5.62 Million
Q4 2020 Feb 17, 2021	BUY	$60.78 - $154.03 $1.43 Million - $3.64 Million	23,600 Added 453.85%	28,800 $4.23 Million
Q3 2020 Nov 17, 2020	SELL	$45.05 - $59.27 $180,200 - $237,080	-4,000 Reduced 43.48%	5,200 $308,000
Q2 2020 Aug 17, 2020	BUY	$42.74 - $66.25 $393,208 - $609,500	9,200 New	9,200 $498,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $452M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.